Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-articular Mesenchymal Stem Cells for Knee Osteoarthritis and Chondral Defects
NCT03477942Phase 1Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Oct 2018
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous mesenchymal stem cells in knee osteoarthritis (OA) and Focal Chondral Defect (FCD) (2 arms), sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection at 24 months. Started Oct 2018; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
knee osteoarthritis (OA)Focal Chondral Defect (FCD)
Beyond the preview
Go deeper on NCT03477942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03477942.